
Pfizer COVID Vaccine May Lead to Vision Loss, Scientists Say
The study, titled Evaluation of the Effects of mRNA-COVID 19 Vaccines on Corneal Endothelium, focused on the changes in the endothelium, the cornea's inner layer, before and after receiving the Pfizer dose. The scientists examined the changes in 64 people's Endothelium before they received their first Pfizer dose and two months after they received their second dose.
The results revealed that taking both doses of Pfizer's COVID-19 vaccine led to fewer endothelial cells in the eye, thicker corneas, and variations in the sizes of these specialized cells, which form the endothelium. The patients did not suffer from clear vision problems during the study. But the results showed that the Pfizer vaccine may temporarily weaken the endothelium.
Pfizer COVID Jab and Vision Loss
During the study, the researchers found out that the Pfizer-BioNTech vaccine led to a roughly two percent increase in micrometers in a patient's cornea. The vaccine caused the patients' cornea thickness to increase from roughly 0.0208 inches to 0.0213 inches, or from 528 to 542 micrometers.
Eye Test Pixabay/Paul Diaconu
The scientists also found that the participants lost around eight percent in the average number of endothelial cells, which keep the cornea clear by pumping out excess fluid. The study revealed that the patients' endothelial cells dropped from 2,597 to 2,378 cells per square millimeter.
Though the normal endothelial cell counts range between 2000 and 3000 cells per square millimeter in healthy adults, an individual with a low cell count due to a disease, infection, or previous eye surgery could be at risk of losing their vision.
The Impact
These small changes may not lead to vision loss in people with healthy eyes in the short term. A slightly thicker cornea may not be harmful because it can temporarily thicken due to fluid buildup, inflammation, or stress on the endothelium from injuries to the eyes or minor illness.
Eye Pixabay/Jonas Zareinia
However, if the cornea remains thick for months or years, it may affect vision by making the cornea less clear. If the researchers find that the impact could last for years, the changes may lead to blurry vision or corneal swelling, especially in individuals who had a corneal transplant or with pre-existing eye problems.
A reduced cell density and thicker cornea could lead to eye conditions, such as corneal decompensation, bullous keratopathy, or corneal edema. These eye conditions could contribute to permanent vision loss if left untreated.
"The endothelium should be closely monitored in those with a low endothelial count or who have had a corneal graft," the scientists warned in the new study, published in the Ophthalmic Epidemiology journal.
Eye Test Pixabay/Paul Diaconu
When and How to Check Endothelial Count?
An individual with eye discomfort or blurry vision can check if the cornea's cells are healthy by consulting an eye doctor. The doctor uses a special microscope called specular microscopy to test if the patient has a low endothelial cell count.
Several factors, such as eye surgeries, infections, or injuries, eye diseases like Fuchs' dystrophy, and aging, can lead to low endothelial cell count. These factors may damage the cells that are responsible for keeping the cornea clear. Another important factor is that these cells don't grow back.
The researchers studied 64 pairs of eyes for this study. The participants took part in the study before they received the Pfizer-BioNTech vaccine. A follow-up was done with the group almost 75 days after they received their second dose of the COVID-19 vaccination. Each participant went through a full eye exam, including scans of the eye's front and back parts, tests for eye pressure, and vision sharpness for ensuring overall eye health.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


International Business Times
2 days ago
- International Business Times
Trump Demands Drug Price Cuts in Letters to 17 Pharma Giants Summary
US President Donald Trump has sent letters to 17 major pharmaceutical companies demanding they cut prescription drug prices in the United States. The letters, released Thursday by the White House, outline his plan to match U.S. prices with those in other developed countries. President Donald Trump addessses the nation after U.S. bombed Iran's nuclear facilities X Trump recently signed an executive order requiring drugmakers to offer "most-favored-nation" pricing. This means companies must sell medications to U.S. patients at the lowest price they offer elsewhere. If drug companies do not comply, Trump warned the government could import cheaper alternatives or take other steps. Companies that received the letters include Pfizer, Eli Lilly, Johnson & Johnson, Merck, Sanofi, and AstraZeneca. Trump had previously criticized earlier proposals from the industry, saying they prioritized profits over patient care. He also demanded that drugmakers return any excess profits made by raising prices overseas to compensate American taxpayers. Shares of major pharmaceutical firms fell after the announcement. Pfizer, Eli Lilly, and Gilead each dropped by around 2%, while a broader index of drug stocks declined 3%. Trump also suggested a system where companies can sell drugs directly to patients, bypassing middlemen, but only if they agree to international pricing rules. The president gave drugmakers a deadline of September 29 to respond with binding commitments. Health experts are skeptical that companies will meet Trump's demands. Some analysts believe the proposals are unlikely to result in immediate price changes, describing them as more political pressure than enforceable policy. Still, several companies, including Pfizer and Novartis, said they are open to working with the administration. Pfizer confirmed its ongoing talks with Trump officials to improve access and affordability for U.S. patients. U.S. drug prices remain among the highest in the world, with patients often paying nearly three times more than those in other developed countries. Drugmakers argue that sharp price cuts could harm innovation, but Trump insists bold action is needed to protect Americans from high costs.

Straits Times
2 days ago
- Straits Times
Pfizer and BioNTech lose UK court appeal over Covid-19 jab
Sign up now: Get ST's newsletters delivered to your inbox Moderna has accused Pfizer and BioNTech of violating its intellectual property rights with regard to mRNA technology. LONDON - US pharmaceutical giant Pfizer and German firm BioNTech lost on Aug 1 a court appeal in the latest step of a multi-million pound battle against US rival Moderna over the Covid-19 vaccine. The Appeals Court in London upheld an earlier UK court decision in the long-running battle between the global pharma firms. It found that one of the European patents held by Moderna was invalid, but that a second one had been broken by Pfizer and its German partner BioNTech. 'The judge made no error of law or principle' in the ruling handed down in July 2024, the Appeal Court judges wrote Friday, dismissing the appeal brought by the two companies. Pfizer quickly said it will appeal the Aug 1 ruling to Britain's Supreme Court. 'Today's UK Court of Appeal's decision does not change our unwavering stance that this patent is invalid,' Pfizer said in a statement. 'This decision has no immediate impact on Pfizer and BioNTech.' Pfizer and BioNTech had argued that both the patents cited by Moderna were invalid, and neither had been infringed. The Aug 1 decision could have wide implications for other cases involving the huge pharma companies in the United States, Germany, Belgium, the Netherlands and Ireland. Moderna said in a statement it was pleased with the Aug 1 ruling and would 'continue to pursue and enforce its patent rights globally to protect its innovative mRNA technology'. A UK court was told in 2024 the firms had spent £19 million (S$32 million) fighting their legal battles. In 2020, Pfizer and BioNTech's vaccine became the first ever mRNA vaccine approved for widespread use, and was swiftly deployed to combat the Covid-19 pandemic. Scientists believe mRNA vaccines, which provoke an immune response by delivering genetic molecules containing the code for key parts of a pathogen into human cells, could be a game-changer against many diseases. Traditional vaccines contain some form of the dead or inactivated target virus. Since the virus need not be grown in the lab, mRNA vaccines can in theory be developed at scale more quickly than traditional vaccines. In March, a German court in Duesseldorf also found Pfizer and BioNTech had violated a Moderna patent filed between 2010 to 2016 to make their vaccines. It ordered they must provide estimates of how much they had profited from breaking the patent as well as provide 'appropriate compensation'. AFP
Business Times
4 days ago
- Business Times
Moderna to cut 10% of staff to offset slowing Covid business
[CAMBRIDGE, MASSACHUSETTS] Moderna is cutting about 10 per cent of its workforce, part of an effort by the struggling biotech company to reduce spending as sales of its Covid vaccine decline. In a note to employees, chief executive officer Stéphane Bancel said the company was 'aligning our cost structure to the realities of our business.' The layoffs will affect hundreds of employees globally, though Bancel did not disclose in which areas of the business. Moderna expects to have fewer than 5,000 employees by the end of the year, he said. It had about 5,800 full-time employees at the end of last year, according to a company filing. Moderna is cutting costs as revenue from its Covid vaccine shrinks and the company faces new challenges from the leadership of Health and Human Services Secretary Robert F Kennedy Jr, a vaccine critic. Under Kennedy, US health officials have rolled back long-standing recommendations regarding Covid shots for children and pregnant women, approved Moderna's updated Covid shot for a narrower group of people and terminated the company's contract to develop bird flu vaccines. Meanwhile Moderna's second product, a vaccine for RSV, has not gained traction. With sales falling short of investors' expectations, Moderna last year pushed back its target to break even by two years, to 2028 from 2026. The company has said it plans to reduce annual operating expenses by about US$1.5 billion by 2027. Moderna is doing that by renegotiating supplier agreements, reducing manufacturing costs and lowering spending on research and development. BLOOMBERG